PRTC
PureTech Health plc
Biotechnology
Market Cap$41M
5Y Perf.-57.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRTC vs CMPS
Revenue, margins, valuation, and 5-year total return — side by side.
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-81.2%
PRTC vs CMPS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRTC | CMPS |
|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities |
| Market Cap | $41M | $902M |
| Revenue (TTM) | $9M | $0.00 |
| Net Income (TTM) | $-56M | $-288M |
| Gross Margin | -196.2% | — |
| Operating Margin | -26.2% | — |
| Total Debt | $20M | $21M |
| Cash & Equiv. | $254M | $150M |
PRTC vs CMPS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRTC
CMPS
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| PureTech Health plc (PRTC) | 100 | 42.5 | -57.5% |
| COMPASS Pathways plc (CMPS) | 100 | 18.8 | -81.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRTC vs CMPS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRTC leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. COMPASS Pathways plc is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PRTC
PureTech Health plc
The Income Pick
PRTC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.51
- -55.9% 10Y total return vs CMPS's -67.6%
- Lower volatility, beta 0.51, Low D/E 6.5%, current ratio 6.59x
Best for: income & stability and long-term compounding
CMPS
COMPASS Pathways plc
The Growth Play
CMPS is the clearest fit if your priority is growth exposure.
- EPS growth -33.9%
- 1.3% margin vs PRTC's -6.2%
- +151.1% vs PRTC's -2.6%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRTC | -3.5% revenue growth vs CMPS's -85.7% |
| Quality / Margins | CMPS | 1.3% margin vs PRTC's -6.2% |
| Stability / Safety | PRTC | Beta 0.51 vs CMPS's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CMPS | +151.1% vs PRTC's -2.6% |
| Efficiency (ROA) | PRTC | -9.9% ROA vs CMPS's -106.8% |
PRTC vs CMPS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCMPSLAGGINGPRTC
PRTCPureTech Health plc
1leads
CMPSCOMPASS Pathways plc
3leads
6 Total Categories
CATEGORYLEADERvs PRTCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CMPS1/1
Valuation MetricsMultiples, price ratios, and targets
CMPS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRTC7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CMPS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRTC and CMPS operate at a comparable scale, with $9M and $0 in trailing revenue.
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| RevenueTrailing 12 months | $9M | $0 |
| EBITDAEarnings before interest/tax | -$228M | -$179M |
| Net IncomeAfter-tax profit | -$56M | -$288M |
| Free Cash FlowCash after capex | -$219M | -$157M |
| Gross MarginGross profit ÷ Revenue | -196.2% | — |
| Operating MarginEBIT ÷ Revenue | -26.2% | — |
| Net MarginNet income ÷ Revenue | -6.2% | — |
| FCF MarginFCF ÷ Revenue | -24.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -30.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -8.7% | -58.7% |
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| Market CapShares × price | $41M | $902M |
| Enterprise ValueMkt cap + debt − cash | -$193M | $774M |
| Trailing P/EPrice ÷ TTM EPS | -0.37x | -3.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.79x | — |
| Price / BookPrice ÷ Book value/share | 0.13x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
CMPS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
PRTC leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
PRTC delivers a -16.1% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-3 for CMPS. On the Piotroski fundamental quality scale (0–9), PRTC scores 5/9 vs CMPS's 2/9, reflecting solid financial health.
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| ROE (TTM)Return on equity | -16.1% | -3.4% |
| ROA (TTM)Return on assets | -9.9% | -106.8% |
| ROICReturn on invested capital | -66.9% | — |
| ROCEReturn on capital employed | -18.8% | -2.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.06x | — |
| Net DebtTotal debt minus cash | -$234M | -$129M |
| Cash & Equiv.Liquid assets | $254M | $150M |
| Total DebtShort + long-term debt | $20M | $21M |
| Interest CoverageEBIT ÷ Interest expense | -1.16x | -52.40x |
PRTC leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CMPS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRTC five years ago would be worth $2,988 today (with dividends reinvested), compared to $2,756 for CMPS. Over the past 12 months, CMPS leads with a +151.1% total return vs PRTC's -2.6%. The 3-year compound annual growth rate (CAGR) favors CMPS at 3.5% vs PRTC's -16.3% — a key indicator of consistent wealth creation.
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| YTD ReturnYear-to-date | +2.0% | +43.4% |
| 1-Year ReturnPast 12 months | -2.6% | +151.1% |
| 3-Year ReturnCumulative with dividends | -41.3% | +11.0% |
| 5-Year ReturnCumulative with dividends | -70.1% | -72.4% |
| 10-Year ReturnCumulative with dividends | -55.9% | -67.6% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +3.5% |
CMPS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PRTC and CMPS each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRTC is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than CMPS's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CMPS currently trades 92.0% from its 52-week high vs PRTC's 85.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 1.33x |
| 52-Week HighHighest price in past year | $19.92 | $10.21 |
| 52-Week LowLowest price in past year | $14.50 | $2.25 |
| % of 52W HighCurrent price vs 52-week peak | +85.2% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 48.2 | 68.1 |
| Avg Volume (50D)Average daily shares traded | 8K | 3.7M |
Evenly matched — PRTC and CMPS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PRTC as "Buy" and CMPS as "Buy". Consensus price targets imply 235.9% upside for PRTC (target: $57) vs 89.9% for CMPS (target: $18).
| Metric | PRTCPureTech Health p… | CMPSCOMPASS Pathways … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $57.00 | $17.83 |
| # AnalystsCovering analysts | 2 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CMPS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). PRTC leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallCOMPASS Pathways plc (CMPS)Leads 3 of 6 categories
Loading custom metrics...
PRTC vs CMPS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRTC or CMPS a better buy right now?
Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRTC or CMPS?
Over the past 5 years, PureTech Health plc (PRTC) delivered a total return of -70.
1%, compared to -72. 4% for COMPASS Pathways plc (CMPS). Over 10 years, the gap is even starker: PRTC returned -55. 9% versus CMPS's -67. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRTC or CMPS?
By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.
51β versus COMPASS Pathways plc's 1. 33β — meaning CMPS is approximately 162% more volatile than PRTC relative to the S&P 500.
04Which is growing faster — PRTC or CMPS?
On earnings-per-share growth, the picture is similar: COMPASS Pathways plc grew EPS -33.
9% year-over-year, compared to -24. 0% for PureTech Health plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PRTC or CMPS?
COMPASS Pathways plc (CMPS) is the more profitable company, earning 0.
0% net margin versus -23. 6% for PureTech Health plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPS leads at 0. 0% versus -21. 1% for PRTC. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PRTC or CMPS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRTC or CMPS better for a retirement portfolio?
For long-horizon retirement investors, PureTech Health plc (PRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51)). Both have compounded well over 10 years (PRTC: -55. 9%, CMPS: -67. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRTC and CMPS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.